Westfield Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-484,777
| Closed | -$66.7M | – | 271 |
|
|
2024
Q2 | $66.7M | Sell |
484,777
-18,416
| -4% | -$2.53M | 0.33% | 98 |
|
|
2024
Q1 | $69.4M | Sell |
503,193
-91,244
| -15% | -$12.5M | 0.36% | 100 |
|
|
2023
Q4 | $78.3M | Sell |
594,437
-54,855
| -8% | -$6.31M | 0.46% | 82 |
|
|
2023
Q3 | $73M | Buy |
649,292
+273,952
| +73% | +$28.8M | 0.5% | 72 |
|
|
2023
Q2 | $35.4M | Buy |
375,340
+120,714
| +47% | +$11.8M | 0.22% | 144 |
|
|
2023
Q1 | $25.8M | Sell |
254,626
-18,062
| -7% | -$1.88M | 0.18% | 158 |
|
|
2022
Q4 | $32.6M | Sell |
272,688
-187,495
| -41% | -$22M | 0.25% | 133 |
|
|
2022
Q3 | $48.9M | Sell |
460,183
-68,662
| -13% | -$6.97M | 0.39% | 103 |
|
|
2022
Q2 | $51.6M | Sell |
528,845
-25,646
| -5% | -$2.37M | 0.41% | 90 |
|
|
2022
Q1 | $52M | Sell |
554,491
-151,735
| -21% | -$12.9M | 0.33% | 104 |
|
|
2021
Q4 | $60.1M | Sell |
706,226
-16,952
| -2% | -$1.56M | 0.36% | 96 |
|
|
2021
Q3 | $69.4M | Buy |
723,178
+108,185
| +18% | +$10.2M | 0.42% | 82 |
|
|
2021
Q2 | $59.9M | Buy |
614,993
+78,743
| +15% | +$7.55M | 0.36% | 104 |
|
|
2021
Q1 | $52.1M | Buy |
536,250
+72,164
| +16% | +$7.57M | 0.32% | 115 |
|
|
2020
Q4 | $44.5M | Buy |
464,086
+59,835
| +15% | +$5.78M | 0.26% | 129 |
|
|
2020
Q3 | $38.9M | Buy |
404,251
+4,785
| +1% | +$554K | 0.25% | 125 |
|
|
2020
Q2 | $48.7M | Sell |
399,466
-248,691
| -38% | -$27.5M | 0.34% | 99 |
|
|
2020
Q1 | $56.1M | Buy |
+648,157
| New | +$63.4M | 0.49% | 73 |
|
|
2019
Q2 | – | Sell |
-316,540
| Closed | -$27.9M | – | 258 |
|
|
2019
Q1 | $27.9M | Buy |
316,540
+172,800
| +120% | +$14.4M | 0.21% | 145 |
|
|
2018
Q4 | $10.3M | Buy |
+143,740
| New | +$13.8M | 0.09% | 187 |
|
|
2018
Q3 | – | Sell |
-184,741
| Closed | -$18.1M | – | 265 |
|
|
2018
Q2 | $18.1M | Buy |
+184,741
| New | +$16.5M | 0.14% | 188 |
|
|
2017
Q4 | – | Sell |
-383,097
| Closed | -$23.5M | – | 262 |
|
|
2017
Q3 | $23.5M | Sell |
383,097
-1,017,488
| -73% | -$53.7M | 0.18% | 170 |
|
|
2017
Q2 | $64.4M | Buy |
1,400,585
+215,102
| +18% | +$10.4M | 0.55% | 66 |
|
|
2017
Q1 | $51.3M | Sell |
1,185,483
-208,022
| -15% | -$8.91M | 0.44% | 82 |
|
|
2016
Q4 | $53.9M | Buy |
1,393,505
+137,510
| +11% | +$6.22M | 0.47% | 79 |
|
|
2016
Q3 | $63.6M | Sell |
1,255,995
-19,580
| -2% | -$975K | 0.51% | 71 |
|
|
2016
Q2 | $58M | Sell |
1,275,575
-42,925
| -3% | -$1.98M | 0.48% | 70 |
|
|
2016
Q1 | $52.1M | Buy |
1,318,500
+96,858
| +8% | +$3.84M | 0.4% | 85 |
|
|
2015
Q4 | $69.1M | Buy |
1,221,642
+75,797
| +7% | +$3.85M | 0.47% | 72 |
|
|
2015
Q3 | $45.6M | Sell |
1,145,845
-27,595
| -2% | -$1.33M | 0.32% | 104 |
|
|
2015
Q2 | $56M | Sell |
1,173,440
-1,114,910
| -49% | -$47.3M | 0.34% | 97 |
|
|
2015
Q1 | $90.9M | Buy |
+2,288,350
| New | +$81.9M | 0.52% | 61 |
|
Other funds holding NBIX
BG
Westfield Capital Management's NBIX Position: Q3 2024 in Review
Westfield Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 484,777 shares — an estimated $66.7M sold.
Westfield Capital Management first reported a position in NBIX in Q1 2015 and held it in 32 quarters. The position peaked at $90.9M in Q1 2015. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.
- Westfield Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
- Westfield Capital Management sold 484,777 Neurocrine Biosciences shares in Q3 2024, an estimated $66.7M.
- Westfield Capital Management first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 32 quarters.
- Westfield Capital Management's Neurocrine Biosciences position peaked at $90.9M in Q1 2015.
- 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.
Based on Westfield Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.